SORIATANE 10 mg capsule
A cohort of 10,402 women aged 15-49 years, starting treatment with acitretin between January 2007 and December 2015, was identified from the French databases SNIIRAM (National Interregional Insurance Information System Illness, reimbursement data) and PMSI (Information Systems Medical Program, hospitalization data). Pregnancy tests were identified from reimbursements of biological tests for (β) hCG, and their frequency was studied according to different time frames in relation to prescription and delivery. Pregnancies have been identified by a hospital stay related to a pregnancy or by a voluntary interruption of medication pregnancy outpatient. The pregnancies selected for their potential teratogenic risk were those in progress at the time of acitretin delivery or that started within two years of the last issue.
http://http://www.meddispar.fr/Actualites/2017/Etude-d-impact-des-mesures-de-reduction-du-risque-teratogene-de-SORIATANE-acitretine-persistance-de-grossesses-en-cours-de-traitement-ou-dans-les-mois-suivant-son-arret#nav-buttons
Sunday, July 2, 2017
Impact study of measures to reduce the teratogenic risk of SORIATANE (acitretin): persistence of pregnancies
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment